Twice a Week and It Grew Hair (Phase 2 Data)

A hair loss drug you only apply twice a week — and it still grew hair in phase 2. GT20029 is the first topical PROTAC ever taken into late-stage human trials. It doesn't block the androgen receptor like RU58841 or topical finasteride. It tags it for destruction. One application keeps working long after the drug clears the scalp — which is how Kintor got results with a twice-weekly schedule. In this video I break down what Kintor actually showed in phase 2, the dose they're betting their pivotal trial on, the safety signal, and how this changes what a serious hair loss stack looks like if it makes it through phase 3. ⸻ 💊 ANAGENINC — 10% off with code: blueprint For building on this protocol with topical research compounds — what most viewers are already running until GT20029 is approved: JXL069 (PP405-inspired research compound) https://anageninc.com/jxl069-solution... RU58841 pre-mixed solution https://anageninc.com/ru58841-solutio... Pyrilutamide https://anageninc.com/pyrilutamide/?r... K&B solution (designed for RU58841) https://anageninc.com/k-b-solution-50... ⸻ 🧴 INTELLIGENT — Shampoo & microneedling — 10% off with code: PHILIPPE Shampoo & microneedling tools https://intelligent.shop/r?id=46ttrr Dermapen https://intelligent.shop/r?id=agfr62 ⸻ 🔴 GROWBAND 2.0 (Hairguard) — $100 off + free shipping, extra 10% with code: blueprint https://www.hairguard.com/?aff=philip... ⸻ 🩸 DR PEN — 10% off with code: BLUEPRINT Microneedling devices (Dr Pen A11, cartridges) and the Stayve Salmon DNA ampoule. Dr Pen microneedling devices https://drpen.net (code BLUEPRINT) Stayve Salmon DNA Gold Ampoule https://drpen.net/products/stayve-sal... ⸻ 📋 What you'll learn in this video: Why most of the GT20029 coverage missed the point How a degrader is fundamentally different from a blocker What Kintor's phase 2 trial actually measured (and what it didn't) The dose Kintor locked in for phase 3 — and why What the safety signal looked like vs. placebo Why twice-weekly dosing is a bigger deal than the hair count 🔗 Full breakdown with sources and updates: 👉 https://www.philippeb.pro/gt20029-pro... [FLAG FOR PHILIPPE: confirm this slug exists or substitute the closest matching article — playbook says never link the homepage. If no matching article exists yet, queue one before publishing.] ⏱ Chapters: 00:00 The headline almost everyone got wrong 00:45 Why twice-a-week is the actual story 02:00 How every existing topical works (and why they have to stay there) 04:00 What a degrader does differently 06:30 The phase 2 trial — what they ran 09:00 The dosing surprise 11:00 The safety signal 12:30 Why compliance is the real win 15:00 Kintor's phase 3 bet 17:00 What this means for your stack right now 💬 If you've been running a daily topical stack for 12+ months — minoxidil, RU58841, JXL069, anything — drop in the comments what you've learned about staying consistent. I read every one. 📚 REFERENCED STUDIES Kintor Pharmaceutical Limited (2024) — GT20029 phase 2 trial results, androgenetic alopecia (Kintor investor disclosure + scientific session presentation) Dhurat et al. (2013) — Microneedling vs. minoxidil controlled trial. Journal of Cutaneous and Aesthetic Surgery Olsen et al. (2006) — Dutasteride vs finasteride head-to-head hair count study Békés, Langley, Crews (2022) — PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery, 21, 181–200 🔔 If this video helped, subscribe — I post one deep-dive like this every month. No fluff, just what's working. ⚠️ Disclaimer: This video is for educational and research purposes only. GT20029 is an investigational drug currently in clinical trials and is not approved for human use outside a sanctioned trial. RU58841, Pyrilutamide, JXL069 and similar compounds are research chemicals and are not FDA-approved for human use. Always consult a qualified medical professional before starting any treatment. #GT20029 #HairLossDrug #PROTAC #Kintor #AndrogenReceptor #HairLossResearch #MaleHairLoss #Finasteride #RU58841 #HairLossStack